Abstract
The superficial bladder cancer is associated with high risk of recurrence and progression, necessitating lengthy follow up and repeated endoscopic treatments. White light cystoscopy (WLC) is the current gold standard for the diagnosis, treatment and surveillance, however the sensitivity and specificity isn’t perfect with risk of missing some tumours. A photodynamic diagnosis (PDD) using Blue-light cystoscopy is a novel concept proposed to overcome the WLC shortcomings. This critical review synthesizes the evidences on the effectiveness of Blue light cystoscopy (BLC) for the diagnosis of non-muscle invasive bladder cancer (NMIBC), and the impact of photodynamic diagnosis on the recurrence rate and progression of superficial bladder cancer.
| Original language | English |
|---|---|
| Journal | Journal of Urology and Nephrology Studies |
| DOIs | |
| Publication status | Published - 22 May 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hexylaminolevulinate-Blue Light Cystoscopy
- Non-muscle invasive bladder cancer
Fingerprint
Dive into the research topics of 'The clinical impact of Hexylaminolevulinate-Blue Light Cystoscopy on non-muscle invasive bladder cancer (NMIBC) recurrence and progression: A critical review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver